Novel of cytokine inhibitors

Abstract

The use of substance that inhibits a pro-inflammatory cytokine, such as TNF or IL-1, for the production of a pharmaceutical composition for improving wound healing is disclosed. Also, a method for improving wound healing wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment is disclosed.

1 - 24 . (canceled)  
   
   
       25 . A method for treating a wound and/or improving wound healing wherein a therapeutically effective amount of a pharmaceutical composition comprising a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment.  
   
   
       26 . A method according to  claim 25 , wherein said pro-inflammatory cytokine is selected from the group consisting of TNF, IL-1, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, GM-CSF, M-CSF, MCP-1, MIP-1, RANTES, ENA-78, OSM, FGF, PDGF, and VEGF.  
   
   
       27 . A method according to  claim 25  or  26 , wherein said pro-inflammatory cytokine is selected from the group consisting of TNF and IL-1.  
   
   
       28 . A method according to  claim 25 , for treatment of posttraumatic tissue injury.  
   
   
       29 . A method according to  claim 28 , wherein said posttraumatic tissue injury is caused by surgery.  
   
   
       30 . A method according to  claim 25 , for treatment of thermic injury.  
   
   
       31 . A method according to  claim 25 , for treatment of a wound resulting from a metabolic process due to reduced nutritional supply.  
   
   
       32 . A method according to  claim 31 , for treatment of a diabetic ulcer, a leg ulcer, a decubitus ulcer or a gastric ulcer.  
   
   
       33 . A method according to  claim 25 , for treatment of a wound resulting from exposure to a toxic compound.  
   
   
       34 . A method according to  claim 25 , wherein said substance is a monoclonal antibody.  
   
   
       35 . A method according to  claim 34 , wherein said substance is selected from the group consisting of infliximab, CDP-571, D2E7 and CDP-870.  
   
   
       36 . A method according to  claim 25 , wherein said substance is a soluble cytokine receptor.  
   
   
       37 . A method according to  claim 36 , wherein said substance is etanercept.  
   
   
       38 . A method according to  claim 25 , wherein said substance is a receptor antagonist.  
   
   
       39 . A method according to  claim 25 , wherein said substance is an antisense oligonucleotide.  
   
   
       40 . A method according to  claim 25 , wherein said substance is an MMP inhibitor selected from the group consisting of tetracyclines, chemically modified tetracyclines, Prinomastat, Batimastat, Marimastat, KB-R7785, TIMP-1, TIMP-2, adTIMP-1, and adTIMP-2.  
   
   
       41 . A method according to  claim 25 , wherein said substance is an quinolones selected from the group consisting of Norfloxacin, Levofloxacin, Enoxacin, Sparfloxacin, Temafloxacin, Moxifioxacin, Gatifloxacin, Gemifloxacin, Grepafloxacin, Trovafloxacin, Ofloxacin, Ciprofloxacin, Pefloxacin, Lomefloxacin, and Temafloxacin.  
   
   
       42 . A method according to  claim 25 , wherein said substance is a thalidomide derivate selected from the group consisting of CC-1088, CDC-501, CDC-801 and Linomide.  
   
   
       43 . A method according to  claim 25 , wherein said substance is selected from the group consisting of prostaglandins, phosphodiesterase 1, 11, 111, IV, and V-inhibitors, cyclosporin, pentoxifyllin derivates, hydroxamic acid derivates, melanin and melancortin agonists, and lazaroids.  
   
   
       44 . A method according to  claim 25 , wherein said substance is a specific IL-1α and/or IL-1β blocking substance.  
   
   
       45 . A method according to  claim 25 , wherein said substance is a non-specific IL-1α and/or IL-1β blocking substance.  
   
   
       46 . A method according to  claim 25 , wherein said substance is lactoferrin or a peptide derived or derivable from lactoferrin.  
   
   
       47 . A method according to  claim 25 , wherein said substance is locally administered.  
   
   
       48 . A method according to  claim 25 , wherein said substance is systemically administered.